CDKN2A and colorectal carcinoma: Recently, it was reported that aberrant methylation of promoter regions of genes as p15, p16INK4a, estrogen receptor, MLH1 and APC – all probably involved in the development of CRC is potentially reversible [9] and therefore may constitute the target for demethylating agents.